Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of myeloma cells treated with IGF-1

ABSTRACT: Objective of this study was to find changes in gene expression of mouse multiple myeloma cells upon treatment with IGF-1

ORGANISM(S): Mus musculus

PROVIDER: GSE17140 | GEO | 2010/02/28

SECONDARY ACCESSION(S): PRJNA119819

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile of myeloma cells treated with IGF-1

Project description:Objective of this study was to find changes in gene expression of mouse multiple myeloma cells upon treatment with IGF-1 Murine multiple myeloma cells were incubated in serum free medium for 12 hours in the absence (3 replicates) or presence (3 replicates) of 100 ng/ml IGF-1

2010-03-09 | E-GEOD-17140 | biostudies-arrayexpress

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA

IGF-1-mediated microRNA profile in glioblastoma

Project description:Insulin-like growth factor (IGF)-1 signaling and micro (mi)RNAs are relevant in mediating GBM progression. However, their roles in desensitizing GBM cells to TMZ are still unclear. We aimed to identify IGF-1-mediated miRNA regulatory networks that elicit TMZ insensitivity for GBM. By miRNA array analyses, totally 1,308 miRNAs were examined. The 93 upregulated and 148 downregulated miRNAs were identified in IGF-1-treated glioma cells.

2019-11-14 | GSE140297 | GEO

LC-MS of LAMP5 in human multiple myeloma cells

Project description:Multiple myeloma (MM)is the second most common tumor of the hematologic system. MM remains incurable at this time. In this study, we used bioinformatics analysis to find key genes in the pathogenesis of MM. We first found that Lysosome associated membrane protein5 (LAMP5) expression was sequentially increased in Multiple myeloma.

2025-09-22 | PXD055882 | Pride

Serum protein N-glycosylation changes in multiple myeloma

Project description:<h4><strong>BACKGROUND:</strong> Multiple myeloma is characterized by clonal proliferation of malignant plasma cells in the bone marrow that produce monoclonal immunoglobulins. N-glycosylation changes of these monoclonal immunoglobulins have been reported in multiple myeloma, but previous studies only detected limited serum N-glycan features.</h4><h4><strong>METHODS:</strong> Here, a more detailed study of the human serum N-glycome of 91 multiple myeloma patients and 51 controls was performed. We additionally analyzed sequential samples from patients (n = 7) which were obtained at different time points during disease development as well as 16 paired blood serum and bone marrow plasma samples. N-glycans were enzymatically released and measured by mass spectrometry after linkage specific derivatization of sialic acids.</h4><h4><strong>RESULTS:</strong> A decrease in both α2,3- and α2,6-sialylation, galactosylation and an increase in fucosylation within complex-type N-glycans were found in multiple myeloma patients compared to controls, as well as a decrease in difucosylation of diantennary glycans. The observed glycosylation changes were present in all ISS stages, including the 'low-risk' ISS I. In individual patients, difucosylation of diantennary glycans decreased with development of the disease. Protein N-glycosylation features from blood and bone marrow showed strong correlation. Moreover, associations of monoclonal immunoglobulin (M-protein) and albumin levels with glycan traits were discovered in multiple myeloma patients.</h4><h4><strong>CONCLUSIONS & GENERAL SIGNIFICANCE: </strong>In conclusion, serum protein N-glycosylation analysis could successfully distinguish multiple myeloma from healthy controls. Further studies are needed to assess the potential roles of glycan trait changes and the associations of glycans with clinical parameters in multiple myeloma early detection and prognosis.</h4>

2022-04-27 | MTBLS676 | MetaboLights

Gene expression profile of OSSL_325096 treated myeloma cells

Project description:OSSL_325096 is a compound that acts as p97/VCP inhibitor and induces apoptosis in myeloma cells. Therefore, we treated KMS12PE and KMS11 myeloma cell lines with OSSL_325096 or DMSO and compare gene expression levels to elucidate the mechanisms of apoptosis.

2019-08-30 | GSE118320 | GEO

Expression data from Igf-1 -/- and Igf-1+/+ mouse cochleas

Project description:Different mutations in the gene encoding humans IGF-I cause intrauterine growth retardation, postnatal growth failure, microcephaly, mental retardation, bilateral sensorineural deafness and multiple dysmorphic features. Insight into the role of IGFs in inner ear cochlear ganglion neurogenesis has come from the study of genetically modified mice. Postnatal cochlear development is severely impaired in mice Igf1-/-, which develop smaller cochlea and cochlear ganglia, an immature tectorial membrane and they display a significant decrease in the number and size of auditory neurons. We used microarrays to define the genetic signatures of Igf-1 +/+ and Igf-1-/- mouse cochea and identify the differentially expressed genes. Keywords: comparison between WT and KO

2008-06-19 | GSE11821 | GEO

Single cell Transcriptomic analysis of CD8+ T cells treated with anti-CD137 agonists within VK12653 Multiple Myeloma bone marrow microenvironment .

Project description:We report the single cell RNA sequencing of mouse CD8+ T cells infiltrating VK12653 Multiple Myeloma lesions upon treatment with anti-CD137 agonists .

2023-06-30 | GSE205702 | GEO

Syntenin inhibition impairs stroma-tumor communication in Multiple Myeloma and improves Bortezomib treatment efficiency

Project description:In multiple myeloma, the objective is to assess the impact of syntenin knockout on the secretory profile of bone marrow stromal cells using the HS-5 model.

2025-07-26 | PXD064458 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data